Whilst weight loss as a result of GLP-1 therapies in humans is believed to be primarily resultant from their inhibitory effect on food intake; distinct neuronal responses should be taken into account when investigating the effects of GLP-1 in neurodegenerative diseases. The gene discussed is GLP1R; the disease is neurodegenerative disease.